Buspirone, Parkinson's disease, and the locus ceruleus

C. L. Ludwig, Daniel Weinberger, G. Bruno, M. Gillespie, K. Bakker, P. A. LeWitt, T. N. Chase

Research output: Contribution to journalArticle

Abstract

Buspirone is a novel anxiolytic whose pharmacological profile differs from that of the benzodiazepines and includes dopaminergic agonist effects. Because of these properties, buspirone's usefulness in the management of idiopathic Parkinson's disease was evaluated in a controlled study of 16 outpatients with stage I-IV disease. At doses of 10 to 60 mg/day, no significant group or individual effects could be discerned on standardized disability, dyskinesia, anxiety, or depression scales. At high dose levels (100 mg/day) however, there was a significant worsening of disability ratings and a decrease in dyskinesia scores; anxiety ratings were also significantly increased. The results indicate that buspirone is well tolerated by parkinsonian patients at conventional antianxiety doses of 10 to 40 mg. Clinical effects of high dose treatment, on the other hand, resemble those associated with a reduction in central dopamine mediated synaptic function. Since buspirone reportedly produces dose-dependent stimulation of norepinephrine containing neurons in the locus ceruleus and behavioral symptoms of such activation were observed, these clinical observations support the concept that central noradrenergic stimulation can adversely affect parkinsonian symptoms.

Original languageEnglish (US)
Pages (from-to)373-378
Number of pages6
JournalClinical Neuropharmacology
Volume9
Issue number4
StatePublished - 1986
Externally publishedYes

Fingerprint

Buspirone
Locus Coeruleus
Parkinson Disease
Dyskinesias
Anxiety
Behavioral Symptoms
Dopamine Agents
Dopamine Agonists
Anti-Anxiety Agents
Benzodiazepines
Dopamine
Norepinephrine
Outpatients
Pharmacology
Depression
Neurons

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Ludwig, C. L., Weinberger, D., Bruno, G., Gillespie, M., Bakker, K., LeWitt, P. A., & Chase, T. N. (1986). Buspirone, Parkinson's disease, and the locus ceruleus. Clinical Neuropharmacology, 9(4), 373-378.

Buspirone, Parkinson's disease, and the locus ceruleus. / Ludwig, C. L.; Weinberger, Daniel; Bruno, G.; Gillespie, M.; Bakker, K.; LeWitt, P. A.; Chase, T. N.

In: Clinical Neuropharmacology, Vol. 9, No. 4, 1986, p. 373-378.

Research output: Contribution to journalArticle

Ludwig, CL, Weinberger, D, Bruno, G, Gillespie, M, Bakker, K, LeWitt, PA & Chase, TN 1986, 'Buspirone, Parkinson's disease, and the locus ceruleus', Clinical Neuropharmacology, vol. 9, no. 4, pp. 373-378.
Ludwig CL, Weinberger D, Bruno G, Gillespie M, Bakker K, LeWitt PA et al. Buspirone, Parkinson's disease, and the locus ceruleus. Clinical Neuropharmacology. 1986;9(4):373-378.
Ludwig, C. L. ; Weinberger, Daniel ; Bruno, G. ; Gillespie, M. ; Bakker, K. ; LeWitt, P. A. ; Chase, T. N. / Buspirone, Parkinson's disease, and the locus ceruleus. In: Clinical Neuropharmacology. 1986 ; Vol. 9, No. 4. pp. 373-378.
@article{d2de0c99d4a34e14b50238845f017f83,
title = "Buspirone, Parkinson's disease, and the locus ceruleus",
abstract = "Buspirone is a novel anxiolytic whose pharmacological profile differs from that of the benzodiazepines and includes dopaminergic agonist effects. Because of these properties, buspirone's usefulness in the management of idiopathic Parkinson's disease was evaluated in a controlled study of 16 outpatients with stage I-IV disease. At doses of 10 to 60 mg/day, no significant group or individual effects could be discerned on standardized disability, dyskinesia, anxiety, or depression scales. At high dose levels (100 mg/day) however, there was a significant worsening of disability ratings and a decrease in dyskinesia scores; anxiety ratings were also significantly increased. The results indicate that buspirone is well tolerated by parkinsonian patients at conventional antianxiety doses of 10 to 40 mg. Clinical effects of high dose treatment, on the other hand, resemble those associated with a reduction in central dopamine mediated synaptic function. Since buspirone reportedly produces dose-dependent stimulation of norepinephrine containing neurons in the locus ceruleus and behavioral symptoms of such activation were observed, these clinical observations support the concept that central noradrenergic stimulation can adversely affect parkinsonian symptoms.",
author = "Ludwig, {C. L.} and Daniel Weinberger and G. Bruno and M. Gillespie and K. Bakker and LeWitt, {P. A.} and Chase, {T. N.}",
year = "1986",
language = "English (US)",
volume = "9",
pages = "373--378",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Buspirone, Parkinson's disease, and the locus ceruleus

AU - Ludwig, C. L.

AU - Weinberger, Daniel

AU - Bruno, G.

AU - Gillespie, M.

AU - Bakker, K.

AU - LeWitt, P. A.

AU - Chase, T. N.

PY - 1986

Y1 - 1986

N2 - Buspirone is a novel anxiolytic whose pharmacological profile differs from that of the benzodiazepines and includes dopaminergic agonist effects. Because of these properties, buspirone's usefulness in the management of idiopathic Parkinson's disease was evaluated in a controlled study of 16 outpatients with stage I-IV disease. At doses of 10 to 60 mg/day, no significant group or individual effects could be discerned on standardized disability, dyskinesia, anxiety, or depression scales. At high dose levels (100 mg/day) however, there was a significant worsening of disability ratings and a decrease in dyskinesia scores; anxiety ratings were also significantly increased. The results indicate that buspirone is well tolerated by parkinsonian patients at conventional antianxiety doses of 10 to 40 mg. Clinical effects of high dose treatment, on the other hand, resemble those associated with a reduction in central dopamine mediated synaptic function. Since buspirone reportedly produces dose-dependent stimulation of norepinephrine containing neurons in the locus ceruleus and behavioral symptoms of such activation were observed, these clinical observations support the concept that central noradrenergic stimulation can adversely affect parkinsonian symptoms.

AB - Buspirone is a novel anxiolytic whose pharmacological profile differs from that of the benzodiazepines and includes dopaminergic agonist effects. Because of these properties, buspirone's usefulness in the management of idiopathic Parkinson's disease was evaluated in a controlled study of 16 outpatients with stage I-IV disease. At doses of 10 to 60 mg/day, no significant group or individual effects could be discerned on standardized disability, dyskinesia, anxiety, or depression scales. At high dose levels (100 mg/day) however, there was a significant worsening of disability ratings and a decrease in dyskinesia scores; anxiety ratings were also significantly increased. The results indicate that buspirone is well tolerated by parkinsonian patients at conventional antianxiety doses of 10 to 40 mg. Clinical effects of high dose treatment, on the other hand, resemble those associated with a reduction in central dopamine mediated synaptic function. Since buspirone reportedly produces dose-dependent stimulation of norepinephrine containing neurons in the locus ceruleus and behavioral symptoms of such activation were observed, these clinical observations support the concept that central noradrenergic stimulation can adversely affect parkinsonian symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0022893596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022893596&partnerID=8YFLogxK

M3 - Article

C2 - 2873889

AN - SCOPUS:0022893596

VL - 9

SP - 373

EP - 378

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 4

ER -